112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

Authors :: B.R. Snyder
Suman Kambhampati
Lewis R. Silverman
Pierre Fenaux
Manoj Maniar
N. Azarnia
Gianluca Gaidano
Karl-Anton Kreuzer
Bart L. Scott
David P. Steensma
Lucy A. Godley
Michael E. Petrone
U. Platzbecker
Aref Al-Kali
Maria R. Baer
Peter L. Greenberg
Ehab Atallah
Gail J. Roboz
G. Garcia-Manero
Mikkael A. Sekeres
Robert H. Collins
Source :: Leukemia Research. 39:S57-S58
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Internal medicine
medicine
Rigosertib
In patient
Hematology
Intensive care medicine
business

Full Text Access

Tools